| Literature DB >> 23677166 |
Nicholas Gulati1, James G Krueger2, Mayte Suárez-Fariñas3, Hiroshi Mitsui1.
Abstract
Entities:
Mesh:
Year: 2013 PMID: 23677166 PMCID: PMC3766390 DOI: 10.1038/jid.2013.190
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551
Figure 1Principal components analysis and immunohistochemistry confirm effective separation of different epidermal regions. (a) Principal components analysis of microarray data. The “Whole Epidermis” data points represent full epidermis LCM performed as part of a separate experiment (Kennedy-Crispin ). (b–h) Immunohistochemical confirmation of transcription factor localization (see Table 1). Immunohistochemistry staining of normal skin samples for: (b) CD11c as a negative control for epidermal staining, (c) pituitary tumortr-ansforming gene 1 (PTTG1), (d) zinc finger protein 281 (ZNF281), (e) regulatory factor X, 5 (RFX5), (f) Sp4 transcription factor (SP4), (g) aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2), and (h) sterol regulatory element-binding transcription factor 2 (SREBF2). Images c–f confirm a basal layer localization while images g–h confirm a suprabasal localization. Scale bar = 100 µm.
Selected transcription factors (identified through Gene Ontology term 0003700) differentially expressed between basal and suprabasal epidermis
| Gene | Description | FCH |
|---|---|---|
| (a) transcription factors upregulated in basal compared to suprabasal epidermis | ||
| pituitary tumor-transforming 1 | 10.303 | |
| zinc finger protein 281 | 9.241 | |
| regulatory factor X, 5 (influences HLA class II expression) | 8.914 | |
| Sp4 transcription factor | 6.347 | |
FDR <0.05 for all genes
reported as differentially expressed by Radoja , but not previously confirmed by immunohistochemistry